Related Experiment Video

Updated: Aug 15, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Is paraoxonase 192 gene polymorphism a risk factor for membranoproliferative glomerulonephritis in children?

Ilmay Bilge1, Aydan Sirin, Bedia Agachan

  • 1Istanbul University, Medical Faculty of Istanbul, Department of Pediatric Nephrology, Istanbul, Turkey. ilmaybilge@superonline.com.

Cell Biochemistry and Function
|September 22, 2005
PubMed

Insights

The AA genotype of paraoxonase (PON1) 192 polymorphism is linked to an increased risk of developing membranoproliferative glomerulonephritis (MPGN) in Turkish children. This genotype also correlates with a poorer disease prognosis and lower serum PON1 activity.

Area of Science:

  • Genetics
  • Nephrology
  • Biochemistry

Background:

  • Paraoxonase (PON1) 192 polymorphism influences serum PON1 activity.
  • Membranoproliferative glomerulonephritis (MPGN) is a serious kidney disease.
  • The role of PON1 in MPGN risk and prognosis is not fully understood.

Purpose of the Study:

  • To investigate the association between PON1 192 polymorphism and serum PON1 activity in Turkish children with MPGN.
  • To determine the impact of PON1 genotype and activity on MPGN risk and prognosis.

Main Methods:

  • Genotyping of PON1 192 polymorphism using PCR, RFLP, and agarose gel electrophoresis.
  • Measurement of serum PON1 activity via spectrophotometric assay.
  • Comparison of genotype frequencies and activity levels between MPGN patients and healthy controls.

Main Results:

  • The frequency of the AA genotype was significantly higher in MPGN patients (61.1%) compared to controls (15.1%).
  • Serum PON1 activity was generally lower in MPGN patients, though not statistically significant.
  • PON1 activity increased with genotypes AA, AB, and BB in both patients and controls.
  • A significant association was found between poor prognosis, AA genotype, and low PON1 activity.

Conclusions:

  • Homozygosity for the PON1 A allele may increase the risk of developing MPGN in Turkish children.
  • The AA genotype and low PON1 activity are associated with a poorer prognosis in pediatric MPGN.
  • PON1 genetic variability significantly affects PON1 activity in Turkish MPGN patients.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...